nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

08.03.2022

Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others

verfasst von: Minoru Satoh, Angela Ceribelli, Tomoko Hasegawa, Shin Tanaka

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Nucleolar staining is one of the standard patterns in immunofluorescence antinuclear antibodies (ANA), seen in 5–9% of ANA in various conditions. Antinucleolar antibodies (ANoA) are classified into 3 patterns in the International Consensus on ANA Patterns (ICAP) classification; AC-8 homogeneous pattern, AC-9 clumpy pattern, and AC-10 punctate pattern. Specificities known to show AC-8 include anti-Th/To, -PM-Scl, -nucleophosmin/B23, -nucleolin/C23, -No55, and others. AC-9 is seen by anti-fibrillarin/U3RNP and AC-10 by anti-RNA polymerase I and hUBF/NOR-90. ANoA has been classically known to be associated with scleroderma (SSc) and the characterization of nucleolar antigens identified several autoantigens recognized by SSc autoantibodies. The clinical association of anti-Th/To, PM-Scl, fibrillarin/U3RNP, and RNA polymerase I with SSc or SSc-overlap syndrome is well established, and commercial assays are developed. Anti-hUBF/NOR90, nucleophosmin/B23, and nucleolin/C23 are known for decades and reported in systemic autoimmune rheumatic diseases (SARDs), malignancies, graft versus host disease (GVHD), and others; however, their clinical significance remains to be established.

Beck JS (1961) Variations in the morphological patterns of “autoimmune” nuclear fluorescence. Lancet 1:1203–1205CrossRef

Fennell RH Jr, Rodnan GP, Vazquez JJ (1962) Variability of tissue-localizing properties of serum from patients with different disease states. Lab Invest 2:24–31

Beck JS, Anderson JR, Mc EA, Rowell NR (1962) Antinucleolar antibodies. Lancet 2:575–577CrossRef

Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo CW, Francescantonio PL et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol 6:412CrossRef

Andrade LEC, Klotz W, Herold M, Conrad K, Rönnelid Y, Fritzler MJ, von Mühlen CA, Satoh M, Damoiseaux J, de Melo Cruvinel W, Chan EKL (2018) On behalf of the Executive Committee of ICAP. International Consensus on Antinuclear Antibody Patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 56:17835–1788

Herold M, Klotz W, Andrade LEC, Conrad K, Damoiseaux J, Fritzler MJ, von Muhlen, Satoh M, Chan EKL (2018) And the other members of the Executive Committee of ICAP. International Consensus on Antinuclear Antibody Patterns on defining negative results and recommendation in reporting unidentified patterns. Clin Chem Lab Med 56:1799–1802

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA Patterns (ICAP) perspective. Ann Rheum Dis 78:879–889CrossRef

Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD et al (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319–2327CrossRef

Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC et al (2020) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 72:1026–1035CrossRef

10.

Terao C, Ohmura K, Yamada R, Kawaguchi T, Shimizu M, Tabara Y et al (2014) Association between antinuclear antibodies and the HLA class II locus and heterogeneous characteristics of staining patterns: the Nagahama study. Arthritis Rheumatol 66:3395–3403CrossRef

11.

Roberts-Thomson PJ, Nikoloutsopoulos T, Cox S, Walker JG, Gordon TP (2003) Antinuclear antibody testing in a regional immunopathology laboratory. Immunol Cell Biol 81:409–412CrossRef

12.

Sener AG, Afsar I, Demirci M (2014) Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods’: four years’ data from Turkey. APMIS 122:1167–1170CrossRef

13.

Mengeloglu Z, Tas T, Kocoglu E, Aktas G, Karabork S (2014) Determination of anti-nuclear antibody pattern distribution and clinical relationship. Pak J Med Sci 30:380–383CrossRef

14.

Gauderon A, Roux-Lombard P, Spoerl D (2020) Antinuclear antibodies with a homogeneous and speckled immunofluorescence pattern are associated with lack of cancer while those with a nucleolar pattern with the presence of cancer. Front Med (Lausanne) 7:165CrossRef

15.

Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S et al (2016) Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol 43:1816–1824CrossRef

16.

Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G et al (1991) Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 18:1826–1832

17.

Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37:15–20CrossRef

18.

Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J et al (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30:332–346CrossRef

19.

Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 42:534–540CrossRef

20.

Sulli A, Ruaro B, Smith V, Pizzorni C, Zampogna G, Gallo M et al (2013) Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol 40:634–639CrossRef

21.

Sharmin S, Ahmed S, Abu Saleh A, Rahman F, Choudhury MR, Hassan MM (2014) Association of immunofluorescence pattern of antinuclear antibody with specific autoantibodies in the Bangladeshi population. Bangladesh Med Res Counc Bull 40:74–78CrossRef

22.

Nishimura S, Nishiya K, Hisakawa N, Chikazawa H, Ookubo S, Nakatani K et al (1996) Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis. Acta Med Okayama 50:261–265

23.

Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592CrossRef

24.

Reddy R, Tan EM, Henning D, Nohga K, Busch H (1983) Detection of a nucleolar 7–2 ribonucleoprotein and a cytoplasmic 8–2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 258:1383–1386CrossRef

25.

Hashimoto C, Steitz JA (1983) Sequential association of nucleolar 7–2 RNA with two different autoantigens. J Biol Chem 258:1379–1382CrossRef

26.

Mahler M, Fritzler MJ, Satoh M (2015) Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. Autoimmun Rev 14:254–257CrossRef

27.

Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ (2002) Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 46:3266–3272CrossRef

28.

Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828CrossRef

29.

Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842–846CrossRef

30.

Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M (1992) Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 35:449–456CrossRef

31.

Kipnis RJ, Craft J, Hardin JA (1990) The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 33:1431–1437CrossRef

32.

Verheijen R, Wiik A, De Jong BA, Hoier-Madsen M, Ullman S, Halberg P et al (1994) Screening for autoantibodies to the nucleolar U3- and Th(7–2) ribonucleoproteins in patients’ sera using antisense riboprobes. J Immunol Methods 169:173–182CrossRef

33.

Van Eenennaam H, Vogelzangs JH, Bisschops L, Te Boome LC, Seelig HP, Renz M et al (2002) Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 130:532–540CrossRef

34.

Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48:203–209CrossRef

35.

Poormoghim H, Lucas M, Fertig N, Medsger TA Jr (2000) Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 43:444–451CrossRef

36.

Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK (2006) Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 130:976–981CrossRef

37.

Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG et al (2006) Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 33:1600–1605

38.

Mahler M, Satoh M, Hudson M, Baron M, Chan JY, Chan EK et al (2014) Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol 41:1334–1343CrossRef

39.

Mahler M, Gascon C, Patel S, Ceribelli A, Fritzler MJ, Swart A et al (2013) Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 15:R50CrossRef

40.

Mahler M, Fritzler MJ (2014) Antinuclear antibodies in children. J Rheumatol 41:1260–1262CrossRef

41.

Markusse IM, Meijs J, de Boer B, Bakker JA, Schippers HPC, Schouffoer AA et al (2017) Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Rheumatology (Oxford) 56:1081–1088

42.

Koenig M, Bentow C, Satoh M, Fritzler MJ, Senecal JL, Mahler M (2019) Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype. Rheumatology (Oxford) 58:1784–1793

43.

Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13:R172CrossRef

44.

Muller R, Benyamine A, Bertin D, Harle JR, Kaplanski G, Mazodier K et al (2020) Characteristics of systemic sclerosis patients with positive anti-Th/To antibodies: about 6 patients and literature review. Rev Med Interne 41:440–445CrossRef

45.

Falkner D, Wilson J, Medsger TA Jr, Morel PA (1998) HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 41:74–80CrossRef

46.

Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83CrossRef

47.

Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477–484

48.

Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487–495CrossRef

49.

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42CrossRef

50.

Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Hoier-Madsen M, Wiik A et al (1998) Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 37:39–45CrossRef

51.

Gunduz OH, Fertig N, Lucas M, Medsger TA Jr (2001) Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum 44:1663–1666CrossRef

52.

Ceribelli A, Satoh M, Chan EK (2012) A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Res Ther 14:R128CrossRef

53.

Hardin JA, Rahn DR, Shen C, Lerner MR, Wolin SL, Rosa MD et al (1982) Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles. J Clin Invest 70:141–147CrossRef

54.

Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N et al (2001) Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology (Oxford) 40:683–686CrossRef

55.

Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902–3912CrossRef

56.

Wolfe JF, Adelstein E, Sharp GC (1977) Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 59:176–178CrossRef

57.

Reichlin M, Maddison PJ, Targoff I, Bunch T, Arnett F, Sharp G et al (1984) Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 4:40–44CrossRef

58.

Reimer G, Scheer U, Peters JM, Tan EM (1986) Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. J Immunol 137:3802–3808CrossRef

59.

Mahler M, Raijmakers R (2007) Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6:432–437CrossRef

60.

Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr (1992) Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations Arthritis Rheum 35:1211–1217CrossRef

61.

Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M (2015) Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17:57CrossRef

62.

Kohara A, Yanaba K, Muro Y, Ito H, Nakagawa H, Noda K et al (2017) Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature. Int J Rheum Dis 20:2186–2189CrossRef

63.

Nishida T, Nakano K, Satoh M, Fukuyo S, Akashi K, Tanaka Y (2021) A Japanese patient with anti-PM/Scl and centromere antibody-positive scleroderma-amyopathic dermatomyositis overlap syndrome who developed renal crisis. Mod Rheumatol Case Rep

64.

Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 31:525–532CrossRef

65.

Jablonska S, Blaszczyk M (1999) Scleroderma overlap syndromes. Adv Exp Med Biol 455:85–92CrossRef

66.

Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M et al (1997) Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40:1257–1266CrossRef

67.

Bell SA, Faust H, Mittermuller J, Kolb HJ, Meurer M (1996) Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol 134:848–854CrossRef

68.

Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM et al (1992) The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 71:327–336CrossRef

69.

Li XZ, McNeilage LJ, Whittingham S (1989) Autoantibodies to the major nucleolar phosphoprotein B23 define a novel subset of patients with anticardiolipin antibodies. Arthritis Rheum 32:1165–1169CrossRef

70.

Ulanet DB, Wigley FM, Gelber AC, Rosen A (2003) Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 49:85–92CrossRef

71.

Lartigue A, Drouot L, Jouen F, Charlionet R, Tron F, Gilbert D (2005) Association between anti-nucleophosmin and anti-cardiolipin antibodies in (NZW x BXSB)F1 mice and human systemic lupus erythematosus. Arthritis Res Ther 7:R1394–R1403CrossRef

72.

Wesierska-Gadek J, Penner E, Hitchman E, Kier P, Sauermann G (1992) Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood 79:1081–1086CrossRef

73.

Brankin B, Skaar TC, Brotzman M, Trock B, Clarke R (1998) Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol Biomarkers Prev 7:1109–1115

74.

Mojtahedi Z, Safaei A, Yousefi Z, Ghaderi A (2011) Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 15:409–418CrossRef

75.

Liu M, Varela-Ramirez A, Li J, Dai L, Aguilera RJ, Zhang JY (2015) Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. Oncol Rep 33:2245–2252

76.

Wang T, Liu M, Zheng SJ, Bian DD, Zhang JY, Yao J et al (2017) Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of alpha-fetoprotein-negative hepatocellular carcinoma. World J Gastroenterol 23:3496–3504CrossRef

77.

Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM (1992) Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140:859–870

78.

Taylor DD, Gercel-Taylor C, Parker LP (2009) Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 115:112–120CrossRef

79.

Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjaer SK, Shih Ie M et al (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122:560–566CrossRef

80.

Dai L, Li J, Xing M, Sanchez TW, Casiano CA, Zhang JY (2016) Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer. Prostate 76:1375–1386CrossRef

81.

Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C et al (2000) Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96:1605–1607CrossRef

82.

Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, Camidge DR et al (2016) Anti-ALK Antibodies in patients with ALK-positive malignancies not expressing NPM-ALK. J Cancer 7:1383–1387CrossRef

83.

Knorr F, Weber S, Singh VK, Pulford K, Reiter A, Woessmann W et al (2018) Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma. Clin Immunol 195:77–81CrossRef

84.

Minota S, Jarjour WN, Roubey RA, Mimura T, Winfield JB (1990) Reactivity of autoantibodies and DNA/anti-DNA complexes with a novel 110-kilodalton phosphoprotein in systemic lupus erythematosus and other diseases. J Immunol 144:1263–1269CrossRef

85.

Yoshikawa H, Komatsu W, Hayano T, Miura Y, Homma K, Izumikawa K et al (2011) Splicing factor 2-associated protein p32 participates in ribosome biogenesis by regulating the binding of Nop52 and fibrillarin to preribosome particles. Mol Cell Proteomics 10:M110 006148

86.

Hirata D, Iwamoto M, Yoshio T, Okazaki H, Masuyama J, Mimori A et al (2000) Nucleolin as the earliest target molecule of autoantibodies produced in MRL/lpr lupus-prone mice. Clin Immunol 97:50–58CrossRef

87.

Valdez BC, Henning D, Busch RK, Woods K, Flores-Rozas H, Hurwitz J et al (1996) A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Nucleic Acids Res 24:1220–1224CrossRef

88.

Arnett FC, Reveille JD, Valdez BC (1997) Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum 40:1487–1492

89.

Garcia MC, Zhou J, Henning D, Arnett FC, Valdez BC (2000) Unique epitopes in RNA helicase II/Gu protein recognized by serum from a watermelon stomach patient. Mol Immunol 37:351–359CrossRef

90.

Fossa A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fossa SD et al (2000) Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer 83:743–749CrossRef

91.

Jansen E, Meulemans SM, Orlans IC, Van de Ven WJ (1997) The NNP-1 gene (D21S2056E), which encodes a novel nuclear protein, maps in close proximity to the cystatin B gene within the EPM1 and APECED critical region on 21q22.3. Genomics 42:336–41

92.

Behrends U, Jandl T, Golbeck A, Lechner B, Muller-Weihrich S, Schmid I et al (2002) Novel products of the HUD, HUC, NNP-1 and alpha-internexin genes identified by autologous antibody screening of a pediatric neuroblastoma library. Int J Cancer 100:669–677CrossRef

93.

Lischwe MA, Ochs RL, Reddy R, Cook RG, Yeoman LC, Tan EM et al (1985) Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine. J Biol Chem 260:14304–10

94.

Reimer G, Pollard KM, Penning CA, Ochs RL, Lischwe MA, Busch H et al (1987) Monoclonal autoantibody from a (New Zealand black x New Zealand white)F1 mouse and some human scleroderma sera target an Mr 34,000 nucleolar protein of the U3 RNP particle. Arthritis Rheum 30:793–800CrossRef

95.

Hultman P, Enestrom S (1988) Mercury induced antinuclear antibodies in mice: characterization and correlation with renal immune complex deposits. Clin Exp Immunol 71:269–274

96.

Hultman P, Enestrom S, Pollard KM, Tan EM (1989) Anti-fibrillarin autoantibodies in mercury-treated mice. Clin Exp Immunol 78:470–477

97.

Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321CrossRef

98.

Okano Y, Steen VD, Medsger TA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100CrossRef

99.

Kasturi KN, Hatakeyama A, Spiera H, Bona CA (1995) Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med 181:1027–1036CrossRef

100.

Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA et al (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39:1151–60

101.

Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis Rheumatology (Oxford) 40:1157–1162CrossRef

102.

Falkner D, Wilson J, Fertig N, Clawson K, Medsger TA Jr, Morel PA (2000) Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 27:1196–1202

103.

Rodriguez-Sanchez JL, Gelpi C, Juarez C, Hardin JA (1987) Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin. J Immunol 139:2579–84

104.

Imai H, Fritzler MJ, Neri R, Bombardieri S, Tan EM, Chan EK (1994) Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. Mol Biol Rep 19:115–24

105.

Dick T, Mierau R, Sternfeld R, Weiner EM, Genth E (1995) Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol 22:67–72

106.

Fritzler MJ, von Muhlen CA, Toffoli SM, Staub HL, Laxer RM (1995) Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 22:521–524

107.

Fujii T, Mimori T, Akizuki M (1996) Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 39:1313–1318CrossRef

108.

Whitehead CM, Fritzler MJ, Rattner JB (1998) The relationship of ASE-1 and NOR-90 in autoimmune sera. J Rheumatol 25:2126–2130

109.

Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB (1997) ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. Chromosoma 106:493–502CrossRef

110.

Edworthy S, Fritzler M, Whitehead C, Martin L, Rattner JB (2000) ASE-1: an autoantigen in systemic lupus erythematosus. Lupus 9:681–687CrossRef

111.

Reimer G, Rose KM, Scheer U, Tan EM (1987) Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 79:65–72CrossRef

112.

Stetler DA, Rose KM, Wenger ME, Berlin CM, Jacob ST (1982) Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease. Proc Natl Acad Sci U S A 79:7499–7503CrossRef

113.

Stetler DA, Jacob ST (1984) Phosphorylation of RNA polymerase I augments its interaction with autoantibodies of systemic lupus erythematosus patients. J Biol Chem 259:13629–13632CrossRef

114.

Stetler DA, Sipes DE, Jacob ST (1985) Anti-RNA polymerase I antibodies in sera of MRL lpr/lpr and MRL +/+ autoimmune mice. Correlation of antibody production with delayed onset of lupus-like disease in MRL +/+ mice. J Exp Med 162:1760–70

115.

Stetler DA, Cavallo T (1987) Anti-RNA polymerase I antibodies: potential role in the induction and progression of murine lupus nephritis. J Immunol 138:2119–2123CrossRef

116.

Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M (1993) Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91:1399–1404CrossRef

117.

Okano Y, Steen VD, Medsger TAJ (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013CrossRef

118.

Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52:2425–2432CrossRef

119.

Jones E, Kimura H, Vigneron M, Wang Z, Roeder RG, Cook PR (2000) Isolation and characterization of monoclonal antibodies directed against subunits of human RNA polymerases I, II, and III. Exp Cell Res 254:163–172CrossRef

120.

Ceribelli A, Krzyszczak ME, Li Y, Ross SJ, Chan JY, Chan EK et al (2011) Atypical clinical presentation of a subset of patients with anti-RNA polymerase III–non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining. Arthritis Res Ther 13:R119CrossRef

121.

Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056CrossRef

122.

Satoh M, Vazquez-Del Mercado M, Krzyszczak ME, Li Y, Ceribelli A, Burlingame RW et al (2012) Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma. Lupus 21:68–74CrossRef

123.

124.

Vermeersch P, Bossuyt X (2013) Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 12:998–1003CrossRef

125.

Daschakraborty S, Aggarwal A, Aggarwal R (2012) Non-organ-specific autoantibodies in Indian patients with chronic liver disease. Indian J Gastroenterol 31:237–242CrossRef

126.

Wu Y, Cai B, Tang J, Bai Y, Wang L (2011) Tacrolimus may induce the production of nucleolar anti-nuclear antibody in liver transplant patients. J Gastrointestin Liver Dis 20:267–270

127.

128.

Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477–484

129.

Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454–2459

130.

Reveille JD (2003) Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 5:160–167CrossRef

131.

Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109

132.

Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R et al (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075CrossRef

133.

Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR et al (2011) Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 30:1333–1339CrossRef

134.

Van Praet JT, Van Steendam K, Smith V, De Bruyne G, Mimori T, Bonroy C et al (2011) Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Rheumatology (Oxford) 50:1302–1309CrossRef

135.

Bonroy C, Van Praet J, Smith V, Van Steendam K, Mimori T, Deschepper E et al (2012) Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 379:53–60CrossRef

136.

137.

Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nunez-Alvarez CA, Torrico-Lavayen R, Garcia-Hernandez JL et al (2011) Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 44:576–584CrossRef

138.

Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD et al (2012) South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 15:102–109CrossRef

139.

Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC et al (2012) Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 12:114–120CrossRef

140.

Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340–354CrossRef

141.

Poormoghim H, Moghadam AS, Moradi-Lakeh M, Jafarzadeh M, Asadifar B, Ghelman M et al (2013) Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 33:1943–1950CrossRef

142.

Wielosz E, Dryglewska M, Majdan M (2014) Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw (Online) 68:987–991CrossRef

143.

Chang WS, Schollum J, White DH, Solanki KK (2015) A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort. New Zealand Clin Rheumatol 34:1921–1927CrossRef

144.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M et al (2015) Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67:3234–3244CrossRef

145.

Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T et al (2017) Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 50:414–421CrossRef

146.

Marou E, Liaskos C, Efthymiou G, Dardiotis E, Daponte A, Scheper T et al (2017) Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Clin Exp Rheumatol 35(Suppl 106):31–34

147.

Liaskos C, Marou E, Simopoulou T, Gkoutzourelas A, Barmakoudi M, Efthymiou G et al (2018) Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece. Mediterr J Rheumatol 29:120–126CrossRef

148.

Liu C, Hou Y, Yang Y, Xu D, Li L, Li J et al (2019) Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. Clin Chim Acta 491:121–125CrossRef

149.

Mendes C, Viana VST, Pasoto SG, Leon EP, Bonfa E, Sampaio-Barros PD (2020) Clinical and laboratory features of African-Brazilian patients with systemic sclerosis. Clin Rheumatol 39:9–17CrossRef

150.

Tahiat A, Allam I, Abdessemed A, Mellal Y, Nebbab R, Ladjouze-Rezig A et al (2020) Autoantibody profile in a cohort of Algerian patients with systemic sclerosis. Ann Biol Clin (Paris) 78:126–133

151.

Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516–522CrossRef

152.

Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231–249CrossRef

153.

Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr (2012) Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30:S12–S16

154.

Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y et al (2014) Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 66:575–584CrossRef

155.

Qin Z, Lavingia B, Zou Y, Stastny P (2011) Antibodies against nucleolin in recipients of organ transplants. Transplantation 92:829–835CrossRef

156.

Fritzler MJ, von Muhlen CA, Toffoli SM, Staub HL, Laxer RM (1995) Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 22:521–524

157.

Dagher JH, Scheer U, Voit R, Grummt I, Lonzetti L, Raymond Y et al (2002) Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 29:1543–1547

158.

Zhang JY, Wang X, Peng XX, Chan EK (2002) Autoantibody responses in Chinese hepatocellular carcinoma. J Clin Immunol 22:98–105CrossRef

159.

Low AH, Wong S, Thumboo J, Ng SC, Lim JY, Ng X et al (2012) Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population. Rheumatology (Oxford) 51:1465–1470CrossRef

Titel: Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others
verfasst von: Minoru Satoh
Angela Ceribelli
Tomoko Hasegawa
Shin Tanaka
Publikationsdatum: 08.03.2022
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2022
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-022-08931-3

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others

Abstract

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis

Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

The Role of Autoantibody Testing in Modern Personalized Medicine

Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis

Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Update HNO